Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison
Condition(s) studied
Study summary
Remifentanil is commonly used as an opioid during general anesthesia. In recent years, several pharmacokinetic/pharmacodynamic (PK/PD) models for target-controlled infusion (TCI) have been developed, with the Eleveld model being one of the most recent and designed for broad applicability.
The aim of this study is to compare the Eleveld TCI model with the routinely used Minto model, in order to evaluate potential differences in the predicted effect-site concentrations (CeR) required to achieve equivalent analgesia levels, as measured by qNOX (CONOX monitor) and the Analgesia Nociception Index (ANI). Post-Tetanic Count (PTC) was also assessed during the maintenance phase to investigate possible differences in nociceptive index responses between the two TCI models.
Eligibility
Primary outcome measure(s)
- Comparison between Concentration at the effector site of Remifentanil (CeR) during anesthesia maintenance — We will consider CeR, qNOX and ANI values during the periprocedural phase
Discover if there are differences between CeR of Eleveld and Minto TCI to aim at the same analgesic depth as measured by qNOX (40-60) and ANI (50-70)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| ULSS2 Marca Trevigiana | Treviso | Italy | Recruiting |
More University of Padova trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07259291 on ClinicalTrials.gov ↗ ← All trials in Italy